GR20060100144A - Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene - Google Patents
Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h geneInfo
- Publication number
- GR20060100144A GR20060100144A GR20060100144A GR20060100144A GR20060100144A GR 20060100144 A GR20060100144 A GR 20060100144A GR 20060100144 A GR20060100144 A GR 20060100144A GR 20060100144 A GR20060100144 A GR 20060100144A GR 20060100144 A GR20060100144 A GR 20060100144A
- Authority
- GR
- Greece
- Prior art keywords
- genes
- pharmaceutical preparations
- encapsulation
- liposomes
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση περιγράφει την οξαλιπλατίνη (oxaliplatin) εγκλεισμένη σε λιποσώματα. Η εν λόγω φαρμακευτική ουσία, είτε σε μονοθεραπεία είτε σε θεραπεία σουνδυσμού με άλλα φαρμακευτικά παρασκευάσματα και αντικαρκινικά γονίδια συνεγκλεισμένα στο λιπόσωμα εγκλεισμού οξαλιπλατίνης, χρησιμοποιείται για τη θανάτωση καρκινικών κυττάρων σε ποικιλία κακοήθων καταστάσεων σε ανθρώπους και ζώα μετά από ενδοφλέβια ένεση. Η εφεύρεση επίσης περιγράφει τον εγκλεισμό περισσοτέρων του ενός διαφορετικών φαρμακευτικών παρασκευασμάτων ή γονιδίων (gene), χρησιμοποιούμενων για την καταπολέμηση καρκινικών κυττάρων, εντός λιποσωμάτων.
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20060100144A GR20060100144A (el) | 2006-03-03 | 2006-03-03 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene |
EP07712997A EP2001441A2 (en) | 2006-03-03 | 2007-03-05 | Cancer treatments |
PCT/GR2007/000015 WO2007099377A2 (en) | 2006-03-03 | 2007-03-05 | Cancer treatments |
AU2007220263A AU2007220263A1 (en) | 2006-03-03 | 2007-03-05 | Cancer treatments |
EA200801912A EA200801912A1 (ru) | 2006-03-03 | 2007-03-05 | Лечение рака |
US12/281,541 US20090053302A1 (en) | 2006-03-03 | 2007-03-05 | Cancer treatments |
RSP-2008/0388A RS20080388A (en) | 2006-03-03 | 2007-03-05 | Cancer treatments |
JP2008556861A JP2009528340A (ja) | 2006-03-03 | 2007-03-05 | 癌治療 |
CA002644566A CA2644566A1 (en) | 2006-03-03 | 2007-03-05 | Cancer treatments |
MX2008011263A MX2008011263A (es) | 2006-03-03 | 2007-03-05 | Tratamientos para cancer. |
BRPI0707059-4A BRPI0707059A2 (pt) | 2006-03-03 | 2007-03-05 | método de formação de uma micela que compreende oxaliplatina, método de encapsulação de oxaliplatina em um lipossomo, micela, lipossomo, lipossomo que compreende uma quantidade eficaz de oxaliplatina, uso de um lipossomo, método de tratamento de cáncer e terapia de combinação |
KR1020087024248A KR20090023548A (ko) | 2006-03-03 | 2007-03-05 | 암 치료 |
CNA2007800139281A CN101522172A (zh) | 2006-03-03 | 2007-03-05 | 癌症治疗 |
MA31204A MA30314B1 (fr) | 2006-03-03 | 2008-09-02 | Traitements contre le cancer |
TNP2008000345A TNSN08345A1 (en) | 2006-03-03 | 2008-09-03 | Cancer treatments |
NO20083927A NO20083927L (no) | 2006-03-03 | 2008-09-15 | Kreftbehandlinger |
ZA200807934A ZA200807934B (en) | 2006-03-03 | 2008-09-16 | Cancer treatments |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20060100144A GR20060100144A (el) | 2006-03-03 | 2006-03-03 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene |
Publications (1)
Publication Number | Publication Date |
---|---|
GR20060100144A true GR20060100144A (el) | 2007-10-17 |
Family
ID=38325437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20060100144A GR20060100144A (el) | 2006-03-03 | 2006-03-03 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene |
Country Status (17)
Country | Link |
---|---|
US (1) | US20090053302A1 (el) |
EP (1) | EP2001441A2 (el) |
JP (1) | JP2009528340A (el) |
KR (1) | KR20090023548A (el) |
CN (1) | CN101522172A (el) |
AU (1) | AU2007220263A1 (el) |
BR (1) | BRPI0707059A2 (el) |
CA (1) | CA2644566A1 (el) |
EA (1) | EA200801912A1 (el) |
GR (1) | GR20060100144A (el) |
MA (1) | MA30314B1 (el) |
MX (1) | MX2008011263A (el) |
NO (1) | NO20083927L (el) |
RS (1) | RS20080388A (el) |
TN (1) | TNSN08345A1 (el) |
WO (1) | WO2007099377A2 (el) |
ZA (1) | ZA200807934B (el) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9186322B2 (en) | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
KR20080094473A (ko) * | 2007-04-20 | 2008-10-23 | 한국화학연구원 | 음이온성 지질나노입자 및 이의 제조방법 |
PL2236145T3 (pl) * | 2008-01-28 | 2014-08-29 | Nanocarrier Co Ltd | Kompozycja farmaceutyczna i lek złożony |
TWI468188B (zh) * | 2008-01-30 | 2015-01-11 | Univ Tokushima | Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation |
CA2753844A1 (en) * | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
WO2010138550A1 (en) * | 2009-05-27 | 2010-12-02 | Northeastern University | Conjugated nanodelivery vehicles |
JP5759464B2 (ja) * | 2009-09-21 | 2015-08-05 | ジェイダブリュー ファーマシューティカル コーポレイション | オキサリプラチンのナノ粒子及びその製造方法 |
JP5817053B2 (ja) * | 2010-04-02 | 2015-11-18 | 国立大学法人 千葉大学 | 腫瘍特異性を有するリポソーム |
CN102133176B (zh) * | 2011-03-22 | 2012-09-05 | 济南宏瑞创博医药科技开发有限公司 | 一种奥沙利铂胶束制剂及其制备方法及应用 |
JP5378469B2 (ja) | 2011-08-11 | 2013-12-25 | 学校法人 日本歯科大学 | 医療用薬剤 |
US10383822B2 (en) | 2012-08-10 | 2019-08-20 | Taiho Pharmaceutical Co., Ltd. | Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same |
MA37931A1 (fr) * | 2012-08-13 | 2016-07-29 | Teni Boulikas | Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite |
KR20150044838A (ko) * | 2012-08-13 | 2015-04-27 | 레귤론, 인코퍼레이티드. | 리포플라틴을 이용한 암 치료방법 |
PL2892524T3 (pl) | 2012-09-04 | 2021-10-25 | Eleison Pharmaceuticals, Llc | Zapobieganie nawrotom płucnym przy użyciu cisplatyny w kompleksie z lipidami |
EA023757B1 (ru) * | 2012-12-24 | 2016-07-29 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения липосомальной формы оксалиплатина |
JP6341987B2 (ja) * | 2013-03-13 | 2018-06-13 | マリンクロッド エルエルシー | がん治療のためのリポソームオキサリプラチン組成物 |
TWI641374B (zh) * | 2013-03-27 | 2018-11-21 | 大鵬藥品工業股份有限公司 | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 |
CN103622912B (zh) * | 2013-12-05 | 2016-02-24 | 常州金远药业制造有限公司 | 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法 |
JP2018505224A (ja) * | 2015-02-13 | 2018-02-22 | オーピーナノ シーオー エルティーディーOP Nano Co.,Ltd. | ナノ粒子を含む組成物並びに腫瘍を治療する方法 |
WO2016141167A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
EP3265063A4 (en) | 2015-03-03 | 2018-11-07 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
KR101687735B1 (ko) * | 2015-09-18 | 2016-12-19 | 서울대학교 산학협력단 | 신규의 동결건조보조제 및 새로운 인지질 용해용 혼합용매를 이용한 리포좀 동결분체의 제조방법 |
US20190307690A1 (en) * | 2016-05-03 | 2019-10-10 | The American University In Cairo | Liposomal Delivery Systems for Oxaliplatin and in Dual Drug Delivery in Combination with Chemo-sensitizing and Chemo-therapeutic agents |
US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
CN106074379B (zh) * | 2016-07-11 | 2019-01-25 | 中国科学院上海药物研究所 | 聚乙二醇化奥沙利铂前药及其制备方法和用途 |
CN112656764B (zh) * | 2020-12-28 | 2022-09-02 | 吉林大学 | 一种紫杉醇铂类共载靶向长循环脂质体及应用 |
CN114814023A (zh) * | 2022-04-24 | 2022-07-29 | 江苏省中医院 | 脂质分子在作为胃癌化疗药耐药的预测性标志物中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6060080A (en) * | 1990-07-16 | 2000-05-09 | Daiichi Pharmaceutical Co., Ltd. | Liposomal products |
CA2046997C (en) * | 1990-07-16 | 2000-12-12 | Hiroshi Kikuchi | Liposomal products |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
EP1292284A2 (en) * | 2000-06-09 | 2003-03-19 | Teni Boulikas | Encapsulation of polynucleotides and drugs into targeted liposomes |
CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
US20040022842A1 (en) * | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
JP3415131B1 (ja) * | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | リポソーム製剤 |
MXPA05001312A (es) * | 2002-08-02 | 2005-08-03 | Transave Inc | Agregados de platino y proceso para producir los mismos. |
WO2004098524A2 (en) * | 2003-05-02 | 2004-11-18 | Aronex Pharmaceuticals, Inc. | Lipid platinum complexes and methods of use thereof |
WO2005000266A2 (en) * | 2003-05-22 | 2005-01-06 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
-
2006
- 2006-03-03 GR GR20060100144A patent/GR20060100144A/el not_active IP Right Cessation
-
2007
- 2007-03-05 WO PCT/GR2007/000015 patent/WO2007099377A2/en active Application Filing
- 2007-03-05 EA EA200801912A patent/EA200801912A1/ru unknown
- 2007-03-05 BR BRPI0707059-4A patent/BRPI0707059A2/pt not_active IP Right Cessation
- 2007-03-05 RS RSP-2008/0388A patent/RS20080388A/sr unknown
- 2007-03-05 CA CA002644566A patent/CA2644566A1/en not_active Abandoned
- 2007-03-05 KR KR1020087024248A patent/KR20090023548A/ko not_active Application Discontinuation
- 2007-03-05 EP EP07712997A patent/EP2001441A2/en not_active Withdrawn
- 2007-03-05 US US12/281,541 patent/US20090053302A1/en not_active Abandoned
- 2007-03-05 AU AU2007220263A patent/AU2007220263A1/en not_active Abandoned
- 2007-03-05 MX MX2008011263A patent/MX2008011263A/es not_active Application Discontinuation
- 2007-03-05 JP JP2008556861A patent/JP2009528340A/ja active Pending
- 2007-03-05 CN CNA2007800139281A patent/CN101522172A/zh active Pending
-
2008
- 2008-09-02 MA MA31204A patent/MA30314B1/fr unknown
- 2008-09-03 TN TNP2008000345A patent/TNSN08345A1/en unknown
- 2008-09-15 NO NO20083927A patent/NO20083927L/no not_active Application Discontinuation
- 2008-09-16 ZA ZA200807934A patent/ZA200807934B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007099377A2 (en) | 2007-09-07 |
TNSN08345A1 (en) | 2009-12-29 |
JP2009528340A (ja) | 2009-08-06 |
CN101522172A (zh) | 2009-09-02 |
US20090053302A1 (en) | 2009-02-26 |
KR20090023548A (ko) | 2009-03-05 |
MX2008011263A (es) | 2008-12-12 |
BRPI0707059A2 (pt) | 2011-04-19 |
CA2644566A1 (en) | 2007-09-07 |
ZA200807934B (en) | 2009-11-25 |
EP2001441A2 (en) | 2008-12-17 |
EA200801912A1 (ru) | 2009-02-27 |
RS20080388A (en) | 2009-07-15 |
MA30314B1 (fr) | 2009-04-01 |
AU2007220263A1 (en) | 2007-09-07 |
NO20083927L (no) | 2008-09-15 |
WO2007099377A3 (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR20060100144A (el) | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene | |
Li et al. | Electromagnetic nanomedicines for combinational cancer immunotherapy | |
PT1156789E (pt) | Terapia para cancros humanos utilizando cisplatina e outros farmacos ou genes encapsulados em lipossomas | |
WO2007084670A8 (en) | Specific therapy using integrin ligands for treating cancer | |
MX339142B (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
MX360098B (es) | Conjugados dirigidos encapsulados en partículas y sus formulaciones. | |
MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
WO2008087025A3 (en) | Specific therapy and medicament using integrin ligands for treating cancer | |
EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
WO2004105782A3 (en) | Drug delivery systems for tumor targeting ngr-molecules and uses thereof | |
WO2009091531A3 (en) | Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery | |
MX336710B (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
WO2010136168A8 (en) | Continuous administration of cilengitide in cancer treatments | |
WO2008022146A3 (en) | Polymer-surfactant nanoparticles for sustained release of compounds | |
WO2005115360A3 (en) | Formulations of anti-pain agents and methods of using the same | |
Yan et al. | Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy | |
ES2186484A1 (es) | Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos. | |
Alexiou et al. | Therapeutic efficacy of ferrofluid bound anticancer agent | |
WO2006124573A3 (en) | Treatment of cancer with 2-deoxyglucose | |
WO2007082742A8 (en) | Isolated organ perfusion combination therapy of cancer | |
WO2014159917A3 (en) | Treatment for exposure to nerve agent | |
WO2010057596A3 (en) | New therapy and medicament using integrin ligands for treating cancer | |
Yu et al. | Fabrication of An Immunostimulatory Supramolecular Nanomedicine for Potent Cancer Chemoimmunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ML | Lapse due to non-payment of fees |
Effective date: 20151002 |